NF-κb / STAT3 Signaling Pathway Collaboration in Diffuse Large B-Cell Lymphoma (DLBCL) Cell-of-Origin (COO) Subtypes: Resolution of Myeloid Subversion By Standard Induction Chemotherapy

Background. Germinal center B-cell (GCB) and activated B-cell (ABC) are two main cell-of-origin (COO) subtypes of diffuse large B-cell lymphomas(DLBCL). Patients presenting with the ABC-DLBCL subtype have inferior outcomes following standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Since ABC-DLBCL phenotype is characterized by marked activation of nuclear factor kappa B (NF-κB) signaling pathway, we hypothesized that inferior outcomes of patients with this COO subgroup treated with standard therapy were due to unresolved innate immune bias or myeloid subversion.